Cefepime vs. cefoperazone/sulbactam in combination with amikacin as empirical antibiotic therapy in febrile neutropenia
- 195 Downloads
Beta lactams are standard empirical therapy for febrile neutropenia (FN). The aim of this study was to evaluate the efficacy and safety of cefepime monotherapy compared with cefoperazone/sulbactam plus amikacin (CS + A) for empirical treatment of high risk FN.
One hundred seventy-five patients with 336 FN episodes were randomized to receive either cefepime (2 g q8h for adults and 50 mg/kg q8h for children) or CS (2 g q8h for adults and 50 mg/kg q8h for children) plus amikacin (15 mg/kg once a day). Positive response was defined as afebrile within 72 h of starting antibiotics, persistent afebrile status more than 48 h and no requirement of second-line antibiotics and antifungal agents.
Three hundred thirty-six episodes were assessable for efficacy (168 cefepime, 168 CS + A). The positive response to antibiotics was identical for cefepime (53%) and CS + A (53%). Positive response was similar in MDI (microbiologically documented infection), 50 vs. 35% (p = 0.248), CDI (clinically documented infection), 50 vs. 35% (p = 0.259), combination CDI + MDI, 25 vs. 15% (p = 0.400), FUO (fever of unknown origin), 68 vs. 72% (p = 0.577) respectively in the two groups. The successful discontinuation of antibiotics at 72 h in FUO was similar in both groups (60 vs. 59%, p = 0.544). Total drug-related adverse events were similar in both groups (8 vs. 6%) except renal dysfunction was high in CS + A (1 vs. 7 events). Mortality was the same between two groups (8 vs 7%).
Cefepime monotherapy and CS + A had similar efficacy as first-line therapy for FN. Discontinuation of empirical antibiotics is safe and feasible approach in selected group of FUO patients.
KeywordsFebrile neutropenia Cefepime Cefoperazone/sulbactam Amikacin
We thank Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER) for providing logistics and other support for carrying out the study. We also thank all the research staffs of the participating departments. Part of this study was presented for poster discussion in ESMO-ASIA 2016 Congress 16 Dec–19 Dec 2016, Singapore, and published as abstract; Annals of Oncology (2016) 27 (suppl_9): ix170-ix176. https://doi.org/10.1093/annonc/mdw599
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Informed consent was obtained from all enrolled patients and study was approved by the Institute Ethics Committee. The study was conducted in accordance with the Declaration of Helsinki and Indian Council of Medical Research (ICMR) guidelines. Study is registered with Clinical Trial Registry, India (CTRI/2017/06/008829).
Study concept and design: Ponraj M, Dubashi B, Kayal S, Cyriac SL, Harish BN, Ranjith K, and Jogamaya P. Provision of patient and study material: Ponraj M, Dubashi B, Kayal S, Cyriac SL, Harish BN, Unni S, and Naresh J. Data collection and analysis: Ponraj M, Kayal S, Dubashi B, Cyriac SL, Jogamaya P, Ranjith K, Unni S, Naresh J, Kiran K, Jagdeep S, Esha J, and Bhanu Prakash. Manuscript writing: Ponraj M, Kayal S, Dubashi B, Cyriac SL, Kiran K, Jagdeep S, Esha J, and Bhanu Prakash. Final approval of the manuscript: all authors.
- 2.Sanz MA, López J, Lahuerta JJ, Rovira M, Batlle M, Pérez C, Vázquez L, Julià A, Palau J, Gutiérrez M, Capote FJ, Ramos F, Benlloch L, Larrea L, Jarque I, Spanish PETHEMA Group (2002) Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial. J Antimicrob Chemother 50:79–88CrossRefGoogle Scholar
- 3.Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of America (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52:e56–e93CrossRefGoogle Scholar
- 4.Averbuch D, Orasch C, Cordonnier C, Livermore DM, Mikulska M, Viscoli C, Gyssens IC, Kern WV, Klyasova G, Marchetti O, Engelhard D, Akova M, on behalf of ECIL4, a joint venture of EBMT, EORTC, ICHS, ESGICH/ESCMID and ELN (2013) European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica 98:1826–1835CrossRefGoogle Scholar
- 5.Babu KG, Lokanatha D, Lakshmaiah KC et al (2016) Bloodstream infections in febrile neutropenic patients at a tertiary cancer institute in South India: a timeline of clinical and microbial trends through the years. Indian J Med Paediatr Oncol Off J Indian Soc Med Paediatr Oncol 37:174–182CrossRefGoogle Scholar
- 6.Sanders CC (1993) Cefepime: the next generation? Clin Infect Dis Off Publ Infect Dis Soc Am 17:369–379Google Scholar
- 9.Bayram I, Erbey F, Alabaz D et al (2009) Cefoperazone-sulbactam plus amikacin empirical therapy for febrile neutropenia in children with cancer. Turk J Med Sci 39:635–640Google Scholar
- 11.Hughes WT, Pizzo PA, Wade JC, Armstrong D, Webb CD, Young LS (1992) Evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis Off Publ Infect Dis Soc Am 15(Suppl 1):S206–S215CrossRefGoogle Scholar
- 14.Tamura K, Matsuoka H, Tsukada J, Masuda M, Ikeda S, Matsuishi E, Kawano F, Izumi Y, Uike N, Utsunomiya A, Saburi Y, Shibuya T, Imamura Y, Hanada S, Okamura S, Gondoh H, Kyushu Hematology Organization for Treatment (K-HOT) Study Group (2002) Cefepime or carbapenem treatment for febrile neutropenia as a single agent is as effective as a combination of 4th-generation cephalosporin + aminoglycosides: comparative study. Am J Hematol 71:248–255CrossRefGoogle Scholar
- 15.Yasuda T, Suzuki R, Ishikawa Y, Terakura S, Inamoto Y, Yanada M, Nagai H, Ozawa Y, Ozeki K, Atsuta Y, Emi N, Naoe T (2013) Randomized controlled trial comparing ciprofloxacin and cefepime in febrile neutropenic patients with hematological malignancies. Int J Infect Dis 17:e385–e390CrossRefGoogle Scholar
- 22.Aynioglu A, Mutlu B, Hacihanefioglu A (2016) A comparison of the efficacy of piperacillin-tazobactam and cefoperazone-sulbactam therapies in the empirical treatment of patients with febrile neutropenia. Rev Espanola Quimioter Publicacion Of Soc Espanola Quimioter 29:69–75Google Scholar
- 27.Jacob LA, Lakshmaiah KC, Govindbabu K, Suresh TM, Lokanatha D, Sinha M, Vijaykumar BR, Sumathi BG, Jayashree RS (2014) Clinical and microbiological profile of febrile neutropenia in solid tumors and hematological malignancies at a tertiary cancer care center in South India. Indian J Cancer 51:464–468CrossRefGoogle Scholar